This inventor holds 1 USPTO granted patent. Top assignee: Behringwerke Aktiengesellschaft. Active years: 1999.
Company Filing History:
Years Active: 1999
Title: Bernd Eisele: Innovator in Pharmaceutical Therapy
Introduction
Bernd Eisele is a notable inventor based in Munich, Germany. He has made significant contributions to the field of pharmaceutical therapy, particularly in the treatment of severe medical conditions. His innovative approach has led to the development of a unique patent that addresses critical health issues.
Latest Patents
Eisele holds a patent for the "Use of C1-inactivation for therapy of certain diseases." This patent describes the use of a C1-inactivator for the production of a pharmaceutical aimed at the prophylaxis and treatment of capillary leak syndrome and circulatory shock. These conditions can arise in severe burns, polytrauma, and during operations involving extracorporeal circulation. The patent also covers the use of cytokines, endogenous mediators, and growth factors produced by genetic engineering in therapeutic applications.
Career Highlights
Throughout his career, Bernd Eisele has been associated with Behringwerke Aktiengesellschaft, a company known for its advancements in biopharmaceuticals. His work has focused on developing therapies that can significantly improve patient outcomes in critical care settings.
Collaborations
Eisele has collaborated with notable colleagues, including Ulrich Delvos and Andreas Jessel. These partnerships have fostered an environment of innovation and have contributed to the advancement of therapeutic solutions in the medical field.
Conclusion
Bernd Eisele's contributions to pharmaceutical therapy through his patent and collaborative efforts highlight his role as an innovator in the medical industry. His work continues to impact the treatment of severe health conditions, showcasing the importance of innovation in healthcare.